| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Journal of Clinical Endocrinology & Metabolism, Vol 48, 1038-1040, Copyright © 1979 by Endocrine Society
ARTICLES |
M Koulu, R Lammintausta and S Dahlstrom
The effect of acute administration of the gamma-amino-butyric acid (GABA) derivative, baclofen, on human GH secretion was tested. In eight of the nine volunteers, both 5 and 10 mg baclofen (Lioresal) significantly basal GH secretion. Previoulsy, it has been reported that subacute baclofen treatment inhibits the GH response to insulin hypoglycemia and arginine. Thus, the present study shows that baclofen is able to modify GH secretion via different mechanisms, depending on the test situation and duration of treatment. As a putative GABA agonist, the effect of baclofen may be mediated via GABA-ergic pathways. Because of variable results, the evaluation of a possible physiological role of GABA in GH secretion requires further study.
This article has been cited by other articles:
![]() |
E. E. Muller, V. Locatelli, and D. Cocchi Neuroendocrine Control of Growth Hormone Secretion Physiol Rev, April 1, 1999; 79(2): 511 - 607. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Macdonald, F. M. Corrigan, D. F. Gaskell, and M. French Enhanced GABAb receptor-mediated transmission in alcohol-dependence syndrome J Psychopharmacol, January 1, 1996; 10(4): 321 - 323. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |